Table 1.
Participant Characteristics
| ID | Lesion level | AIS | Age (yr) | Sex | Height (cm) | Mass (kg) | TPI (yr) | Injury cause | History of anticholinergic use |
|---|---|---|---|---|---|---|---|---|---|
| 1 | C4 | A | 51 | F | 167 | 55 | 8 | MVA | Oxybutynin 5 mg BID |
| 2 | C4 | A | 37 | F | 165 | 64 | 14 | MVA | Oxybutynin 5 mg TID |
| 3 | C5 | C | 43 | M | 175 | 84 | 27 | MVA | Oxybutynin 5 mg BID |
| 4 | C5 | C | 62 | M | 180 | 98 | 4 | Fall | Oxybutynin 5 mg BID |
| 5 | C6 | A | 44 | M | 183 | 63 | 19 | Sport | Tolterodine tartrate 12 mg OD |
| 6 | C6 | B | 60 | M | 178 | 70 | 34 | MVA | Oxybutynin 5 mg BID |
| 7 | C6 | C | 43 | M | 183 | 81 | 24 | Sport | Fesoterodine fumarate 4 mg OD |
| 8 | C7 | A | 42 | F | 178 | 53 | 18 | MVA | Oxybutynin 5 mg BID |
| 9 | C7 | B | 40 | M | 172 | 66 | 17 | Fall | Solifenacin succinate 10 mg OD |
| 10 | C7 | B | 28 | M | 178 | 68 | 8 | MVA | Oxybutynin 5 mg TID |
| 11 | C8 | B | 46 | M | 165 | 45 | 40 | MVA | Oxybutynin 2.5mg BID |
| 12 | T3 | B | 38 | M | 182 | 95 | 21 | Sport | Oxybutynin 10 mg BID |
| 13 | T4 | A | 36 | F | 178 | 63 | 23 | Sport | Tolterodine tartrate 2 mg BID |
| 14 | T5 | A | 31 | M | 178 | 60 | 10 | Sport | Oxybutynin 5 mg BID |
| 15 | T5 | A | 46 | F | 165 | 73 | 29 | Fall | Fesoterodine fumarate 8 mg OD |
| 16 | T5 | A | 62 | M | 183 | 91 | 42 | MVA | Tolterodine tartrate LA 4 mg OD |
| 17 | T5 | A | 44 | M | 157 | 70 | 18 | Fall | Fesoterodine fumarate 8 mg OD |
| Mean ± SD | 11 C 6 T |
9 A 5 B 3 C |
44 ± 10 | 5 F 12 M |
175 ± 8 | 71 ± 15 | 21 ± 11 | 4 Fall 8 MVA 5 Sport |
3 Tolterodine tartrate 10 Oxybutynin 3 Fesoterodine fumarate 1 Solifenacin succinate |
AIS, American Spinal Injury Association Impairment Scale; BID, twice daily; C, cervical; MVA, motor vehicle accident; OD, once daily; T, thoracic; TID, three times daily; TPI, time post-injury.